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Summary
 
Histocompatibility leukocyte antigen (HLA)-A2 is used as a restricting element to present sev-
eral melanoma-associated antigen (MAA)-derived peptides to cytotoxic T lymphocytes (CTLs).
HLA-A2 antigen is selectively lost in primary melanoma lesions and more frequently in me-
tastases. Only scanty information is available about the molecular mechanisms underlying this
abnormality, in spite of its potentially negative impact on the clinical course of the disease and
on the outcome of T cell–based immunotherapy. Therefore, in this study we have shown that
the selective HLA-A2 antigen loss in melanoma cells 624MEL28 is caused by a splicing defect
of HLA-A2 pre-mRNA because of a base substitution at the 5
 
9
 
 splice donor site of intron 2 of
the HLA-A2 gene. As a result, HLA-A2 transcripts are spliced to two aberrant forms, one with
exon 2 skipping and the other with intron 2 retention. The latter is not translated because of an
early premature stop codon in the retained intron. In contrast, the transcript with exon 2 skip-
ping is translated to a truncated HLA-A2 heavy chain without the 
 
a
 
1
 
 domain. Such a polypep-
tide is synthesized in vitro but is not detectable in cells, probably because of the low steady state
level of the corresponding mRNA and the low translation efficiency. These results indicate
that a single mutational event in an HLA class I gene is sufficient for loss of the corresponding
allele. This may account, at least in part, for the high frequency of selective HLA class I allele
loss in melanoma cells. Our conclusion emphasizes the need to implement active specific im-
munotherapy with a combination of peptides presented by various HLA class I alleles. This
strategy may counteract the ability of melanoma cells with selective HLA class I allele loss to es-
cape from immune recognition.
Key words: histocompatibility leukocyte antigen class I • splicing defect • truncated heavy 
chain • melanoma
 
I
 
mmunohistochemical staining with mAbs has convinc-
ingly documented abnormalities in HLA class I antigen
expression in primary melanoma lesions and more fre-
quently in metastases (1). These defects range from total HLA
class I antigen loss to selective loss of one of the HLA class I
allospecificities encoded within a melanoma cell (2–6). The
clinical significance of HLA class I antigen downregulation
in melanoma cells is suggested by its association with a poor
clinical course of the disease (7) and by its negative impact
on the outcome of increasingly applied T cell–based immu-
notherapy (8, 9). These findings have stimulated interest in
the characterization of the molecular lesions underlying ab-
normalities in HLA class I antigen expression by melanoma
cells and their effects on the interactions of melanoma cells
with immune cells. Information derived from these studies
contributes to our understanding of the molecular mecha-
nism(s) used by melanoma cells to escape from immune
surveillance and may eventually suggest strategies to correct
these defects.
The molecular lesions causing total HLA class I antigen
loss have been characterized in several melanoma cell lines
(6, 10–12). Mutations have been identified in 
 
b
 
2
 
-microglo-
bulin (
 
b
 
2
 
-
 
m
 
)
 
1
 
 gene(s) which inhibit its translation in most
cases and its transcription in rare cases (6, 10–12). These
mutations, which appear to represent an early event in the
 
1
 
Abbreviations used in this paper:
 
 
 
b
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2-microglobulin; FITC-GAM,
FITC-conjugated goat anti–mouse Ig antibodies; IEF, isoelectric focus-
ing; IIF, indirect immunofluorescence; MAA, melanoma-associated anti-
gen(s); RT, reverse transcription. 
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progression of the malignant phenotype (12),
 
 
 
range from sin-
gle base substitutions to partial gene deletion (10–12). Total
HLA class I antigen loss by melanoma cells has marked ef-
fects on their
 
 
 
in vitro interactions with cytotoxic lymphocytes.
It causes resistance to lysis by melanoma-associated antigen
(MAA)-specific, HLA class I antigen–restricted CTLs (6, 12),
and enhances their susceptibility to lysis by NK cells (13).
The molecular mechanism(s) underlying the spontaneous
selective loss of an HLA class I allele by melanoma cells has
not yet been investigated. To the best of our knowledge,
the only available information in this regard
 
 
 
derives from
the analysis of the melanoma cell line SK-MEL-29.1.22,
which had selectively lost HLA-A2 antigens in vitro after
 
g
 
-irradiation and selection with MAA-specific, HLA-A2–
restricted CTLs (14, 15). The functional significance of the
selective HLA class I allele loss has been investigated in a
few cases. Loss of an HLA class I allele causes in vitro resis-
tance of melanoma cells to lysis by MAA-specific CTLs,
which use the lost allele as a restricting element (14, 16, 17).
To broaden our knowledge of the molecular mechanisms
underlying the selective HLA class I allele loss by melanoma
cells, in this study we have characterized
 
 
 
the molecular le-
sion responsible for selective HLA-A2 antigen loss in the
melanoma cell line 624MEL28. We have selected the
HLA-A2 allele for our studies, since this allele has the high-
est frequency in patients with melanoma as well as in the
control population,
 
 
 
and has been found to be selectively
lost in primary melanoma lesions and more frequently in
metastases (3, 4). Furthermore, this allele has been found to
present the largest number of MAA-derived peptides to
CTLs (18, 19) and to be the
 
 
 
restricting element for a large
array of MAA-derived peptides that have been effectively
used to implement active specific immunotherapy in pa-
tients with melanoma (20, 21).
 
Materials and Methods
 
Cytokine.
 
Recombinant human IFN-
 
g
 
 was obtained from
Hoffmann-La Roche, Inc.
 
Cells.
 
The human melanoma cell lines 624MEL28 and
624MEL38 (17) and the B lymphoid cell line Raji were cultured at
37
 
8
 
C in a 5% CO
 
2
 
 atmosphere in RPMI 1640 medium (GIBCO
BRL) supplemented with 10% Serum plus (Hazelton Biologics, Inc.).
 
mAbs and Conventional Antisera.
 
The mAb W6/32, which
recognizes a monomorphic determinant expressed on 
 
b
 
2
 
-
 
m
 
–asso-
ciated HLA-A,B,C heavy chains; the mAb LGIII-220.6, which rec-
ognizes a determinant preferentially expressed on 
 
b
 
2
 
-
 
m
 
–associated
HLA-A heavy chains; the mAb H2-89.1, which recognizes a deter-
minant preferentially expressed on 
 
b
 
2
 
-
 
m
 
–associated HLA-B heavy
chains; the anti–HLA-A2,A28 mAbs CR11-351, HO-4, and HO-5;
the anti–HLA-A2,B17 mAbs HO-2 and MA2.1; the anti–HLA-B7
cross-reacting group mAb KS4; and the mAb HC-A2, which rec-
ognizes a determinant restricted to 
 
b
 
2
 
-
 
m
 
–free HLA-A heavy
chains, were developed and characterized as described elsewhere
(22–27). The rabbit anti–
 
b
 
2
 
-
 
m
 
–free HLA class I heavy chain se-
rum R5996-4 (28) and the rabbit anti-HLA class I heavy chain
cytoplasmic tail serum were obtained from Dr. N. Tanigaki
(Roswell Park Cancer Institute) and Dr. H.L. Ploegh (Harvard
Medical School, Boston, MA), respectively. Purified rabbit anti–
mouse Ig antibodies and FITC-conjugated goat anti–mouse Ig
antibodies (FITC-GAM) were purchased from Jackson Immuno-
Research Laboratories.
 
Synthetic Oligonucleotide Primers and Probes, and HLA-A2 Gene.
 
The HLA class I–specific synthetic oligonucleotide primers and
probes listed in Table I were synthesized on a BioSearch Cyclone
DNA synthesizer (MilliGen/BioSearch), with the exception of
those obtained from Dr. S.Y. Yang (Memorial Sloan-Kettering
Cancer Center, New York). Oligonucleotide probes were radio-
labeled with [
 
g
 
-
 
32
 
P]ATP (
 
.
 
5,000 Ci/mmol; Nycomed Amer-
sham plc) in the presence of T4 polynucleotide kinase (29).
The plasmid RSV.5neo-HLA-A2.1 was obtained from Dr. P.
Cresswell (Yale University School of Medicine, New Haven, CT).
The HLA-A2 cDNA for synthesis of RNA probe was con-
structed by cloning a 500-bp EagI/PstI fragment from plasmid
RSV.5neo-HLA-A2.1 into pCR-Script™ SK(
 
1
 
) cloning vector
in an antisense orientation. The EagI/PstI fragment contains most
of the exon 2 and exon 3 of the HLA-A2 cDNA. The RNA
probe was synthesized by in vitro transcription using MAXI-
script™ T
 
7
 
 kit (Ambion, Inc.) with [
 
a
 
-
 
32
 
P]UTP (800 Ci/mmol;
Amersham Pharmacia Biotech) following the manufacturer’s in-
structions. The synthesized RNA probe was purified through a 5%
polyacrylamide gel and eluted following the procedure recom-
mended by the manufacturer. The HLA-A2 cDNA containing the
whole coding region and the HLA-A2 cDNA lacking exon 2 to be
used for
 
 
 
in vitro translation were amplified by PCR from plasmid
RSV5neo-HLA-A2.1 and melanoma 624MEL28 cells, respec-
tively, using the primers 5P2 and 3P2. PCR products were cloned
into SalI/HindIII sites of pCR-Script™ SK(
 
1
 
) cloning vector.
The plasmid pHLA-A2, which carries the entire HLA-A2
gene including its regulatory sequences, and the neomycin resis-
tance gene (30) were obtained from Dr. J.L. Strominger (Harvard
University, Cambridge, MA).
 
Indirect Immunofluorescence.
 
Indirect immunofluorescence (IIF)
staining was performed as described elsewhere (4). After staining,
cells were analyzed by cytofluorometry on a FACS
 
®
 
 analyzer (Bec-
ton Dickinson). Results are expressed as log fluorescence intensity.
 
Immunochemical Methods.
 
Radiolabeling of cells, indirect im-
munoprecipitation, SDS-PAGE under reducing conditions, iso-
electric focusing (IEF), and fluorography were performed as de-
scribed elsewhere (10, 31).
Western blotting was performed as described elsewhere (32),
with the modification that antibodies bound to proteins trans-
ferred to filters were detected using the ECL™ Western blotting
detection reagents kit (Amersham Pharmacia Biotech) following
the manufacturer’s instructions.
 
Transfection of Cells with a Wild-type HLA-A2 Gene.
 
Plasmid
pHLA-A2 was transfected into cells using the electroporation
method as described (10). After transfection, cells were cultured
for 2 wk in medium supplemented with G418-sulfate at the final
concentration of 0.4 mg/ml. Cell colonies were picked up and
expanded in medium supplemented with G418-sulfate at the final
concentration of 0.2 mg/ml.
 
Amplification by PCR of cDNA and Genomic DNA.
 
cDNA was
reverse transcribed from total RNA as described (33). Genomic
DNA was prepared from cells using the cell lysis method (34).
Amplification of cDNA and genomic DNA was performed as de-
scribed elsewhere (15) using a DNA Thermal Cycler (Perkin-
Elmer Cetus).
 
DNA Hybridization Analysis.
 
PCR products were size frac-
tionated, transferred to nylon membranes, and hybridized with
probes as described elsewhere (15).
 
DNA Sequencing.
 
DNA sequencing was performed as de- 
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scribed elsewhere (35), using the Sequenase
 
 
 
version 2.0 kit
(United States Biochemical Corp.). PCR products were directly
sequenced using products recovered from an agarose gel using
the Geneclean II kit (Bio 101 Inc.). After denaturation at 98
 
8
 
C
for 10 min in the presence of 10% DMSO, PCR products were
cooled in ethanol/dry ice and then sequenced.
 
RNase Protection Assay.
 
The RNase protection assay was per-
formed using the RPA II™ Ribonuclease protection assay kit
(Ambion, Inc.) following the manufacturer’s instructions, except
for increasing the hybridization temperature to 45
 
8
 
C.
 
In Vitro Translation of HLA-A2 mRNA.
 
HLA-A2 mRNA was
translated in vitro using the TNT
 
®
 
 T
 
7
 
 coupled reticulocyte lysate
system (Promega Corp.) following the manufacturer’s instruc-
tions. The translation products were analyzed by SDS-PAGE un-
der reducing conditions.
 
Results
 
Lack of HLA-A2 Antigen Cell Surface Expression by
624MEL28 Cells.
 
The clone 624MEL28 was isolated by
limiting dilution from the melanoma cell line 624MEL
(HLA-A2, -A3, -B7, -B14, -Cw7, -Cw8), which had been
established from a metastatic lesion (17). This cell line was
subcloned at the 35th passage, since the broad profile of the
IIF staining with mAbs suggested marked heterogeneity in
HLA-A2 antigen expression. The clone 624MEL28 was
not stained in IIF by anti–HLA-A2,B17 mAb HO-2 and
anti–HLA-A2,A28 mAbs HO-4 and HO-5, all of which
stained the autologous HLA-A2 antigen–bearing clone
624MEL38 (Fig. 1). The lack of staining of the 624MEL28
cells by anti–HLA-A2 mAb is not due to loss of an antigenic
determinant, since the three mAbs used recognize distinct
determinants on HLA-A2 heavy chains (Ferrone, S., unpub-
lished results).
 
 
 
The HLA-A2 antigen loss is selective, since,
like the autologous clone 624MEL38, 624MEL28 cells were
stained strongly by anti–HLA-A,B,C mAb W6/32 and by
anti–HLA-A mAb LGIII-220.6, and weakly by anti–HLA-B
mAb H2-89.1 and anti–HLA-B7 cross-reacting group mAb
KS4 (Fig. 1). It is noteworthy that the intensity of staining
by the latter six mAbs of the clone 624MEL28 is compara-
ble to that of the autologous clone 624MEL38. Further-
more, IFN-
 
g
 
 did not induce HLA-A2 antigen expression
by 624MEL28 cells, since they were not stained by anti–
HLA-A2 mAbs after a 72-h incubation at 37
 
8
 
C with IFN-
 
g
 
(100 U/ml; Fig. 1). These findings indicate that 624MEL28
cells have selectively lost HLA-A2 antigens.
 
Lack of Wild-type HLA-A2 Heavy Chain Synthesis by
624MEL28 Cells.
 
624MEL28 cells used as a source of HLA
class I antigens for immunoprecipitation experiments were
treated with IFN-
 
g
 
 in order to increase the level of HLA
class I antigen expression. No component was detected by
 
Table I.
 
HLA Class I–specific Oligonucleotide Primers and Probes
 
Synthetic
oligonucleotide Sequence (5
 
9
 
–3
 
9
 
) Exon
Location
position Specificity
5
 
9
 
 primers
5pEh CCCGAAGGCGGTGTATGGAT
 
*
 
2
 
237–
 
2
 
217 HLA class I
5pUT CAGATTCTCCCCAGACGCCG
 
*
 
2
 
24–
 
2
 
3 HLA class I
5pE1A2 TCCTGCTACTCTCGGGGGCT 1 22–41 HLA-A2
AP31
 
‡
 
CGTCCCCAGGCTCTCACTCCAT 2
 
2
 
9–13 HLA class I
5pE2A
 
§
 
GACGCCGCGAGCCAGAGGAT 2 114–133 HLA-A
5pE3A2 GCGGACATGGCATCTCAGAC 3 135–155 HLA-A2,A28
5P2
 
i
 
GCGCGTCGACCCCAGACGCCGAG
GATGGCC 1
 
2
 
13–6 HLA class I
3
 
9
 
 primers
AP2
 
‡
 
TCACTTTCCGTGCTCCCC 2 186–203 HLA-A2
3pE3A2 CTCCCACTTGTGCTTGGTGG 3 154–173 HLA-A2,A28
3pE3
 
§
 
TGCAGCGTCTCCTTCCCGTT 3 248–267 HLA class I
3P2
 
i
 
CCGCAAGCTTTCTCAGTCCCA
CACAAGGCAGCTGTC 8 6–35 HLA class I
3pE8A AGTCACAAAGGGAAGGGCAGG 8 46–66 HLA class I
Probes
95V
 
§
 
CACACCGTCCAGAGG 3 7–21 HLA-A2,A69
161D
 
§
 
CTGGATGGCACGTGC 3 207–222 HLA-A3
 
*
 
5
 
9
 
-flanking region of class I gene.
 
‡
 
Described by Fernandez-Vina et al. (reference 55).
 
§
 
Described by Oh et al. (reference 56), and obtained from Dr. S.Y. Yang.
 
i
 
Described by Ennis et al. (reference 57). 
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IEF analysis in the immunoprecipitates with anti–HLA-A2,
A28 mAb CR11-351 and with anti–HLA-A2,B17 mAb
MA2.1 from intrinsically radiolabeled 624MEL28 cells
(Fig. 2). Furthermore, HLA-A2 heavy chains were not de-
tected by
 
 
 
IEF in the immunoprecipitates with mAb W6/32
and with rabbit antiserum R5996-4. However, the latter
immunoprecipitates contain HLA-A3, -B7, and -B14 heavy
chains. These immunochemical findings corroborate the
results of binding assays and indicate that 624MEL28 cells
do not synthesize wild-type HLA-A2 heavy chains.
 
Induction of HLA-A2 Antigen Expression by 624MEL28 Cells
after Transfection with a Wild-type HLA-A2 Gene.
 
To investi-
gate whether HLA-A2 antigen expression by 624MEL28 cells
could be reconstituted by transferring a wild-type HLA-A2
gene, cells were transfected with a plasmid containing both a
wild-type HLA-A2 gene and a neomycin resistance gene.
Two clones selected in medium supplemented with G418
were both stained in IIF by anti–HLA-A2,B17 mAb HO-2
(Fig. 3). The staining intensity was increased when cells were
incubated for 72 h at 37
 
8
 
C with IFN-
 
g
 
 (100 U/ml; data
not shown). These results indicate that the lack of HLA-A2
antigen expression by 624MEL28 cells is caused by struc-
tural abnormality(ies) in the HLA-A2 gene.
 
Detection of Two Alternative Forms of HLA-A2 mRNA in
624MEL28 Cells.
 
Reverse transcription (RT)-PCR am-
plification of the mRNA corresponding to a region span-
ning from the middle of exon 1 to exon 3 of the HLA-A2
gene yielded a 218- and a 729-bp product from 624MEL28
cells. The latter product is 241 bp larger than the one am-
plified from 624MEL38 cells with the expected size of 488
bp, whereas the former product is 270 bp smaller. Both
RT-PCR products are HLA-A2 specific, since they hy-
bridized with the HLA-A2,A69–specific probe 95V (Fig.
4 A). These results indicate that there are two forms of the
HLA-A2 mRNA in 624MEL28 cells, one with a 270-base
deletion and the other with a 241-base fragment inclusion.
The size of deleted and inserted fragments is compatible
with that of exon 2 and intron 2 of the HLA-A2 gene, re-
spectively, suggesting the lack of the sequence correspond-
ing to exon 2 or insertion of intron 2 in HLA-A2 mRNA.
Figure 1. Selective lack of cell surface HLA-A2 antigen expression by
624MEL28 cells. 624MEL28 (a) and 624MEL38 (b) cells were incubated
at 378C for 72 h with IFN-g (100 U/ml). 624MEL28 (c) and 624MEL38
(d) cells incubated under the same experimental conditions but without
IFN-g were used as controls. At the end of the incubation, cells were
harvested, washed with PBS, and incubated with anti–HLA-A2,B17 mAb
HO-2, anti–HLA-A2,A28 mAbs HO-4 and HO-5, anti-HLA class I
mAb W6/32, anti–HLA-A mAb LGIII-220.6, anti–HLA-B mAb H2-
89.1, and anti–HLA-B7 cross-reacting group mAb KS4. After washings
with PBS, cells were stained with FITC-GAM. Fluorescence intensity
was determined on a FACS® analyzer (Becton Dickinson). Background
was determined by incubating cells with FITC-GAM alone (control).
Figure 2. Lack of HLA-A2 heavy chain synthesis by 624MEL28 cells.
624MEL28 and 624MEL38 cells were incubated at 378C for 72 h with
IFN-g (100 U/ml). Cells were metabolically radiolabeled with [32S]me-
thionine and lysed with 1% NP-40. After indirect immunoprecipitation
with anti–b2-m–free HLA class I heavy chain rabbit serum R5996-4,
anti-HLA class I mAb W6/32, anti–HLA-A2,B17 mAb HO-2, and anti–
HLA-A2,A28 mAb CR11-351, antigens were analyzed by IEF on a slab
gel apparatus. Gels were then processed for fluorography.
Figure 3. Induction of HLA-A2
antigen expression by 624MEL28
cells after transfection with a wild-
type HLA-A2 gene. HLA-A2
gene–transfected 624MEL28
clones 2 (a) and 3 (b) were incu-
bated with anti–HLA-A2,B17
mAb HO-2. After washings with
PBS, cells were stained with
FITC-GAM. Fluorescence inten-
sity was determined on a FACS®
analyzer (Becton Dickinson).
Nonspecific fluorescence was de-
termined by incubating cells with
FITC-GAM alone. 624MEL28
cells that were not transfected
with HLA-A2 gene (c) were used
as an HLA-A2–negative control.
The anti–HLA-B mAb H2-89.1
was used for comparison.209 Wang et al.
These possibilities were corroborated by the generation of
a 571-bp product, but not of a 330-bp product when
cDNA corresponding to exons 2 and 3 of the HLA-A2
gene was isolated from 624MEL28 cells and amplified by
PCR (Fig. 4 B). Exon 2 skipping and insertion of intron 2
in the two aberrant forms of HLA-A2 mRNA identified in
624MEL28 cells were conclusively proven by DNA sequenc-
ing of the 729-, 571-, and 218-bp RT-PCR products. Only
the sequences of exons 1 and 3 of the HLA-A2 gene were
found in the 218-bp RT-PCR product (Fig. 5). The se-
quence of intron 2 of the HLA-A2 gene was found in both
the 729- and the 571-bp RT-PCR products. It is note-
worthy that the sequence of intron 1 was not detected in
the 729-bp RT-PCR product, indicating that the latter
was derived from the mature HLA-A2 mRNA with intron
2 retention. A T to A base substitution was found at posi-
tion 2 in intron 2. This mutation results in a splicing defect,
since the U at this position in pre-mRNA is required for
spliceosome recognition for pre-mRNA splicing. As shown
in Fig. 6, the intron 2 retention causes a reading frameshift,
which introduces the stop codon TGA at position 6–8 of the
unspliced intron 2. Thus, the synthesis of the HLA-A2
polypeptide encoded by the large HLA-A2 transcript is
blocked. In contrast, the small HLA-A2 transcript is in frame
in spite of the exon 2 skipping. Therefore, a truncated
HLA-A2 heavy chain lacking the a1 domain is expected to
be synthesized by 624MEL28 cells. No additional mutation
was found in the remaining sequence of HLA-A2 cDNA.
Mutation at the 59 Splice Donor Site in Intron 2 of the HLA-A2
Gene in 624MEL28 Cells. To define the molecular lesion
responsible for exon 2 skipping in the HLA-A2 mRNA, the
region from exon 1 to exon 3 of the HLA-A2 gene was am-
plified from genomic DNA of 624MEL28 cells using HLA-
A2–specific primers. Only the PCR products with the ex-
Figure 4. Detection of two alternative
forms of HLA-A2 cDNA amplified by RT-
PCR from 624MEL28 cells. HLA class I
heavy chain cDNA was synthesized from
RNA isolated from 624MEL28 cells by re-
verse transcriptase reaction using HLA class
I–specific 39 primer 3pE3. HLA-A2 cDNA
was amplified by PCR using the two pairs
of HLA-A2–specific primer (A and B).
HLA-A locus cDNA was amplified using an
HLA-A locus–specific primer pair (C). The
regions from which the primers are derived
are indicated below each panel. The corre-
sponding exon regions in the cDNA are in-
dicated by numbers. RT-PCR products
were subjected to Southern blotting and hy-
bridized with HLA-A2,A69–specific probe
95V or HLA-A3–specific probe 161D as
indicated. DNA amplified from HLA-A2–pos-
itive 624MEL38 cells and from HLA-A2–neg-
ative Raji cells were used as HLA-A2–posi-
tive and –negative controls, respectively.
DNA amplified from HLA-A3–negative
SKMEL-29.1 cells was used as a negative
control for HLA-A3.
Figure 5. Identification of exon 2 skipping
and intron 2 retention in HLA-A2 cDNA
from 624MEL28 cells. The 218- and 729-bp
RT-PCR products amplified from RNA iso-
lated from 624MEL28 cells using HLA-A2–
specific primers 5pE1A2 and 3pE3A2 were
purified from agarose gel using a Geneclean II
(Bio 101 Inc.) kit. RT-PCR products were
then sequenced using a Sequenase 2.0 kit
(United States Biochemical Corp.). The auto-
radiography of the sequencing gels for these
RT-PCR products is shown as indicated.
The 488-bp RT-PCR products amplified
from 624MEL38 cells were sequenced using
the same primers as a normal control.210 Splicing Defect of HLA-A2 Pre-mRNA in Melanoma
pected size of 980 bp were amplified from 624MEL28 cells as
well as from the autologous 624MEL38 cells, which express
HLA-A2 antigens (data not shown). These results rule out the
presence of additional HLA-A2 gene copies with exon 2 de-
letion in 624MEL28 cells. Furthermore, DNA sequencing of
the four clones containing the 980-bp PCR product identi-
fied a T to A substitution at position 2 of the 59 splice donor
site in intron 2 (Fig. 7). This mutation is the same mutation
found in the large mutated HLA-A2 cDNA. No mutation
was found at the 39 acceptor site in introns 1 and 2 of the
HLA-A2 gene. Therefore, the mutation at position 2 of in-
tron 2, which inactivates the 59 splice donor site, is responsi-
ble for both exon 2 skipping and intron 2 retention in the
HLA-A2 mRNA in 624MEL28 cells.
Marked Reduction of the Steady State Level of the Mutated
HLA-A2 mRNA in 624MEL28 Cells. Although the HLA-
A2 mRNA with exon 2 skipping in 624MEL28 cells was ex-
pected to synthesize a truncated polypeptide, such a polypep-
tide was not detected by SDS-PAGE analysis of antigens im-
munoprecipitated from intrinsically labeled 624MEL28 cells
by the anti–b2-m–free HLA class I heavy chain xenoantiserum
R5996-4 or by an anti-HLA class I heavy chain cytoplasmic
tail xenoantiserum. Furthermore, the truncated HLA-A2
polypeptide was not detected by testing a 624MEL28 cell ex-
tract with the two xenoantisera in Western blotting. To deter-
mine whether these results reflect a dramatic decrease in the
level of the HLA-A2 mRNA lacking the exon 2 sequence be-
cause of the splicing defect, its steady state mRNA level in
624MEL28 cells was measured using the RNase protection
assay. A 32P-labeled antisense HLA-A2 RNA complementary
to 496 bp of the region spanning most of exons 2 and 3 of the
HLA-A2 gene was used as a probe. As shown in Fig. 8, diges-
tion with RNase of this probe protected by mRNA isolated
from 624MEL28 cells yielded a 268- and a 496-base fragment.
The 268-base fragment, which has the same size as exon 3 in
the probe, is derived from the probe protected from RNase di-
gestion by the HLA-A2 mRNA lacking the exon 2 sequence.
The protection of the probe by mRNA from 624MEL38 cells
did not yield this fragment. The 496-base fragment is likely to
derive from the probe protected by the HLA-A2 mRNA with
unspliced intron 2, since a fragment with the same size was
generated from the probe protected by the RNA synthesized
in vitro by an HLA-A2 genomic DNA fragment containing
exon 2, intron 2, and exon 3. This fragment is unlikely to de-
rive from protection by a wild-type HLA-A2 mRNA from
624MEL28 cells, since such an mRNA was not detected by
RT-PCR in these cells. The level of the 268- and 496-base
fragments protected by mRNA isolated from 624MEL28 cells
is very low, at least 20-fold less than that of the 496-base frag-
ment derived from the probe protected by  the wild-type
HLA-A2 mRNA isolated from control 624MEL38 cells.
These results suggest that the steady state level of HLA-A2
mRNA with exon 2 skipping is too low to produce a detect-
able level of truncated HLA-A2 heavy chain.
In Vitro Translation of HLA-A2 mRNA with Deletion of the
Segment Corresponding to Exon 2. Translation experiments
Figure 6. Comparison of nucleotide and deduced amino acid se-
quences of the two forms of HLA-A2 cDNA from 624MEL28 cells with
those of the wild-type HLA-A2.1 cDNA. The coding region and de-
duced amino acid sequences of HLA-A2 cDNA corresponding to exon 1,
exon 2, and part of exon 3 of the wild-type HLA-A2 cDNA (WT) and of
the HLA-A2 cDNA with exon 2 skipping (ST) and intron 2 retention
(LT) isolated from 624MEL28 cells are compared. Dashes and blanks in-
dicate sequence identity and deletion, respectively. Intron 2 retention is
indicated by a large arrowhead. The stop codon is underlined.
Figure 7. Identification of a base substitution in intron 2 of the HLA-A2
gene and alternative splicing of HLA-A2 pre-mRNA in 624MEL28 cells.
Exon 2 and intron 2 segments of the HLA-A2 gene were amplified by
PCR from genomic DNA of 624MEL28 cells using the HLA-A2–
specific primer pair 5pE1A2 and 3pE3. HLA-A2 DNA amplified from
624MEL38 cells was used as a control. DNA was sequenced using a Se-
quenase 2.0 kit. The exon 2–intron 2 boundary and the first two nucle-
otides of intron 2 are indicated in the DNA sequencing gel (top). The
splicing of HLA-A2 pre-mRNA in 624MEL28 cells is compared dia-
grammatically with that of wild-type HLA-A2 pre-mRNA (bottom).211 Wang et al.
using a transcription/translation-coupled system tested
whether the HLA-A2 mRNA lacking the exon 2 sequence
can synthesize proteins in vitro. To this end, the mutated
HLA-A2 cDNA containing the whole coding sequence,
except the exon 2–encoded region, was isolated from
624MEL28 cells and used for in vitro mRNA synthesis. A
35-kD polypeptide, z10 kD smaller than the wild-type,
was synthesized by mutated HLA-A2 mRNA (Fig. 9 A).
The loss of the a1 domain, which is encoded by exon 2,
accounts for the reduction in size of the synthesized poly-
peptide. This interpretation is consistent with the results of
the SDS-PAGE analysis of the translation products immu-
noprecipitated by three xenoantibodies. The truncated
polypeptide was not immunoprecipitated by mAb HC-A2,
which recognizes a determinant expressed on the a1 do-
main of b2-m–free HLA class I heavy chains (36), but was
immunoprecipitated by the anti–b2-m–free HLA class I
heavy chain xenoantiserum R5996-4 (Fig. 9 B) and by the
anti-HLA class I heavy chain cytoplasmic tail xenoantise-
rum (data not shown). These results indicate that the HLA-A2
mRNA with exon 2 skipping synthesizes in vitro a trun-
cated HLA class I heavy chain lacking the a1 domain. It is
noteworthy that the intensity of the 35-kD translation
product is about twice as low as that of the 44.6-kD trans-
lation product (Fig. 9, A and C), although the extent of
RNA synthesis by the mutated and the wild-type HLA-A2
cDNA is similar, as measured by the level of [32P]UTP in-
corporation (Fig. 9 D). Therefore, the efficiency of in vitro
translation of the HLA-A2 mRNA with exon 2 skipping is
lower than that of the wild-type HLA-A2 mRNA.
Discussion
This study has characterized for the first time the molec-
ular lesion underlying the spontaneous selective loss of an
HLA class I allele by melanoma cells. HLA-A2 antigen has
been selectively lost by melanoma cells 624MEL28 because
of a defect in the splicing of HLA-A2 pre-mRNA. Pre-
mRNA is spliced into two aberrant forms of mature
mRNA, one with exon 2 skipping and the other with in-
tron 2 retention. The latter mRNA form is distinct from
Figure 8. Reduced steady state level of the aberrant HLA-A2 mRNA
in 624MEL28 melanoma cells. 624MEL28 cells were incubated at 378C
for 72 h with IFN-g (100 U/ml). Control cells were incubated under the
same experimental conditions, but without IFN-g. At the end of the in-
cubation, total cellular RNA was extracted from cells and hybridized with
a 32P-labeled HLA-A2 riboprobe (496 bases) and with a 32P-labeled hu-
man b-actin riboprobe (250 bases). After hybridization, RNA was di-
gested by RNase, and the generated fragments were size fractionated by
5% PAGE. Gels were autoradiographed for 1 or 7 d. RNA from
624MEL38 and Raji cells were used as HLA-A2–positive and –negative
controls, respectively. (A) RNA synthesized in vitro by an HLA-A2 ge-
nomic fragment containing exon 2, intron 2, and exon 3 (RNA) was used
to identify the fragments generated by RNase digestion from the probe
protected by the HLA-A2 mRNA containing intron 2. (B) The frag-
ments generated by RNase digestion from the probe protected by a wild-
type HLA-A2 mRNA, by HLA-A2 mRNA with exon 2 skipping, and
by HLA-A2 mRNA with intron 2 retention are shown diagrammatically.
Figure 9. In vitro synthesis of a truncated HLA class I heavy chain by
HLA-A2 mRNA with exon 2 skipping isolated from 624MEL28 cells. The
cloned HLA-A2 cDNA lacking exon 2 sequence (E22 A2) was used as a
template for mRNA synthesis. The synthesized mRNA was translated in
the presence of [35S]methionine in a coupled transcription/translation sys-
tem driven by T7 promoter (Promega Corp.). A wild-type HLA-A2 cDNA
(A2) was used as a control. Translation products were analyzed by SDS-
PAGE (A) or were immunoprecipitated by the rabbit anti–b2-m–free HLA
class I heavy chain serum R5996-4 and by the anti–b2-m–free HLA heavy
chain mAb HC-A2 before analysis by SDS-PAGE (B). Normal rabbit se-
rum (NRS) was used as a negative control. The degree of translation was
quantitated by scanning densitometry of the intrinsically radiolabeled pro-
teins in the gel (C). The level of RNA synthesis was measured by [32P]UTP
incorporation obtained from TCA precipitation (D).212 Splicing Defect of HLA-A2 Pre-mRNA in Melanoma
pre-mRNA since it does not contain the sequences of in-
trons 1, 3, 4, 5, 6, and 7. The mRNA with intron 2 reten-
tion cannot be translated into a wild-type HLA-A2 heavy
chain, since the intron 2 retention introduces a premature
stop codon at position 6–8 of the unspliced intron. The
mRNA form with exon 2 skipping is expected to be trans-
lated into a truncated HLA-A2 heavy chain lacking the a1
domain. Although detected in in vitro translation experi-
ments, such a polypeptide was not detected in 624MEL28
cells by testing cell extracts with xenoantibodies to distinct
domains of HLA class I antigens in indirect immunoprecip-
itation and Western blotting assays. The latter finding may
reflect the very low steady state level of the mRNA form
with exon 2 skipping, as measured by the RNase protec-
tion assay, and the low translation efficiency, as suggested
by the results of in vitro translation experiments.
The abnormal splicing of the HLA-A2 mRNA in
624MEL28 cells is caused by a mutation at position 2 of the
59 splice donor site in intron 2, which is highly conserved
in mammalian cells (37). This mutation inactivates the 59
splice donor site, since pre-mRNA splicing requires the U
at this position for spliceosome recognition (38). The im-
portance of the conserved nucleotide at this position has
been proven with site-directed mutagenesis experiments in
which replacement of the T with a purine prevented in
vivo splicing of the 12S mRNA (39) and in vitro splicing
of b-globin mRNA (40). The base substitution at the 59
splice donor site in intron 2 of the HLA-A2 gene results ei-
ther in exon 2 skipping or in intron 2 retention in the two
aberrant transcripts of the HLA-A2 gene in 624MEL28
cells, since no HLA-A2 gene copy with exon 2 deletion or
with normal sequence at the 59 splice donor site of intron 2
was detected in 624MEL28 cells.
The occurrence of either exon skipping or intron reten-
tion in pre-mRNA splicing caused by the same mutation at
the 59 splice donor site of an intron is an uncommon phe-
nomenon. To the best of our knowledge, this abnormality
has been detected only in the type III procollagen gene in
members of a family with aortic aneurysms and easy bruis-
ability (41) and in the b-hexoaminidase a chain gene in an
Ashkenazi Jewish patient with Tay-Sachs disease (42). In
both cases, as in our own, exon skipping and intron reten-
tion were caused by a mutation in the splice site at the 59
end of the mutated intron. Exon skipping is a predominant
phenotype caused by mutations at the 59 splice donor site
of an intron in mammalian cells (43). The mutation of a 59
splice donor site inhibits the interaction of spliceosome
with the 39 and 59 splice sites across the exon so that it
blocks exon definition (44). If no cryptic site is activated,
splicing of the exon leads directly to exon skipping. In con-
trast, intron retention is a rare phenomenon, found in only
z6% of the cases with alternative splicing in mammalian
cells (43). In the splicing of a small intron, the spliceosome
uses the intron as the initial mode for selection of splice sites.
A mutation of a 59 splice donor site in a small intron leads to
intron retention (45). The mutated intron 2 of the HLA-A2
gene in 624MEL28 cells is a small intron, as it is z241 bp in
size. Thus, it is likely that “exon and intron definition,” two
recognition mechanisms, are used for selection of splice sites
in the splicing of HLA-A2 pre-mRNA.
The aberrant splicing of the HLA-A2 mRNA in the
melanoma cell line 624MEL28 is different in several re-
spects from the alternative splicing that results in skipping
of exon 5 in the mRNA for HLA class I heavy chains (46)
and of exon 3 or of both exons 3 and 4 in the mRNA for
HLA-G heavy chains (47). First, exon 5 skipping may oc-
cur in the mRNA for both HLA-A and -B locus gene
products in the same cell line. Second, more than one exon
may be skipped in the mRNA for HLA-G heavy chain. Fi-
nally, normally spliced mRNA encoding the various anti-
gens is more abundant than the corresponding mRNA re-
sulting from alternative splicing. In contrast, in 624MEL28
cells exon 2 is skipped only in the mRNA transcribed by a
mutated HLA class I heavy chain gene. No normally
spliced HLA-A2 mRNA was detected in 624MEL28 cells.
To the best of our knowledge, the molecular lesion of
the HLA-A2 gene identified in 624MEL28 cells is the first
to have been characterized in a melanoma cell line with a
spontaneous selective HLA class I allele loss. This lesion is
distinct from that found in the g-irradiation–induced
HLA-A2 loss mutant melanoma cell line SK-MEL-29.1.22
in which a partial deletion of the HLA-A2 gene results in
its transcriptional blockade (15). Furthermore, the molecu-
lar defect in 624MEL28 cells is different from the lesions
underlying HLA class I  allelic losses in other malignant
cells. Deletion and transcriptional downregulation of the
HLA-A11 gene cause selective loss of this allele in a colon
carcinoma (48) and in a Burkitt’s lymphoma (49) cell line,
respectively. Furthermore, mutations in the HLA class I
gene itself or in the upstream promoter region are likely to
underlie the selective loss of HLA class I alleles described in
two colon and two cervical carcinoma cell lines (50, 51). It is
noteworthy that one single mutational event is sufficient to
cause the selective loss of an HLA class I allospecificity. In
contrast, at least two mutational events that inactivate the
two B2m genes present in a cell are required to cause total
HLA class I antigen loss. This difference may account for the
higher frequency of a selective HLA class I allele loss than of
total HLA class I antigen loss in melanoma cells (52).
Preliminary results suggest that the HLA-A2 antigen loss
624MEL28 melanoma cells do not induce an MAA-spe-
cific CTL response restricted by the expressed HLA class I
alleles. These findings, which parallel similar data in mouse
model systems (53, 54), could account for the escape of
HLA-A2 antigen loss melanoma cells from CTL-mediated
recognition and for the high frequency of selective HLA-
A2 loss in metastatic melanoma lesions (1, 4). The negative
impact of these variants on the outcome of T cell–based
immunotherapy emphasizes the need to design strategies to
induce MAA-specific CTL responses restricted not only by
HLA-A2 antigens, but also by the other HLA class I alleles
present in HLA-A2–positive patients with melanoma. An
alternative, although not exclusive, strategy is to combine
T cell–based immunotherapy with immunotherapeutic
modalities that are not negatively affected by HLA class I
antigen loss by melanoma cells.213 Wang et al.
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